Every Form 4 that Minerva Neurosciences, Inc (NERV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NERV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NERV filings page.
Minerva Neurosciences, Inc. reported that director Inderjit Kaul received a grant of 12,147 stock options to purchase common stock at an exercise price of $3.97 per share, expiring on August 2, 2036. All 12,147 options are reported as directly held after the grant.
Vesting is performance- and time-based: 25% vests on November 14, 2026; 45% vests on the tenth day after a public announcement that a Phase 3 confirmatory trial of roluperidone in schizophrenia met its primary endpoint at 12 weeks; and the remaining 30% vests on the tenth day after public announcement of safety data from the 40-week relapse assessment phase, in each case while Kaul provides services under a consulting agreement dated November 14, 2025.
Minerva Neurosciences, Inc. reported that SVP, CFO and Secretary Frederick W. Ahlholm received a grant of stock options covering 680,000 shares of Common Stock. The options have an exercise price of $4.6800 per share and expire on June 2, 2036.
According to the footnote, the option vests 25% on June 3, 2027 and then in equal quarterly installments over three years. Following this grant, Ahlholm holds 680,000 stock options directly, and the filing does not show any related share sales or purchases.
Minerva Neurosciences CEO Remy Luthringer received a new stock option grant. The award covers 1,690,700 options to buy Minerva common stock at an exercise price of $4.68 per share. The option vests 25% on June 3, 2027, with the remainder vesting in equal quarterly installments over the following three years, and expires on June 2, 2036.
Minerva Neurosciences director Fouzia Laghrissi-Thode received a stock option grant covering 50,000 shares of common stock. The option has an exercise price of $4.68 per share and expires on June 2, 2036. It vests in four equal quarterly installments, with the first 12,500 shares vesting three months after June 3, 2026 and additional 12,500-share tranches vesting every three months thereafter, subject to her continued service as a non-employee director. This filing reports a compensation-related award rather than any open-market buying or selling of shares.
Minerva Neurosciences director David Kupfer received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036. Following this award, he holds options for 50,000 shares directly.
The grant vests in four equal quarterly installments, with one-quarter vesting three months after June 3, 2026 and an additional quarter vesting every three months thereafter, subject to his continued service as a non-employee director on each vesting date.
Minerva Neurosciences director Inderjit Kaul received a new stock option grant as equity compensation. The award covers 50,000 shares of common stock at an exercise price of $4.68 per share and is held directly.
The option vests in four equal quarterly installments, with one quarter of the total shares vesting three months after June 3, 2026 and the remaining quarters vesting every three months thereafter, provided Kaul continues to serve as a non-employee director on each vesting date. Following this grant, Kaul holds options covering 50,000 shares, and there were no open-market purchases or sales reported.
Minerva Neurosciences, Inc. director G Jan Van Heek received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036.
The 50,000 options vest in four equal quarterly installments, with one-quarter vesting three months after June 3, 2026 and additional quarters vesting every three months after that. Vesting requires continued service as a non-employee director on each vesting date.
Minerva Neurosciences director Hans Peter Hasler received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036. Following the grant, he holds 50,000 options directly.
The award vests in four equal quarterly installments. One quarter of the options vests three months after June 3, 2026, with an additional quarter vesting every three months thereafter, as long as he continues serving as a non-employee director on each vesting date.
Minerva Neurosciences Chief Business Officer and General Counsel James Joseph O'Connor received a grant of 350,800 employee stock options for common stock. The options have an exercise price of $6.97 per share and are held directly.
The option award vests 25% on April 21, 2027, with the remaining shares vesting in equal quarterly installments over the following three years, and expires on April 20, 2036. This is a compensation-related grant, not an open-market share purchase or sale, and leaves him holding 350,800 options after the transaction.
Minerva Neurosciences director Inderjit Kaul received a stock option grant for 12,169 shares of Common Stock at an exercise price of $6.03 per share. The option expires on March 30, 2036 and is structured as performance- and time-based compensation, not an open-market share purchase or sale.
According to the vesting terms, 25% of the option vests on November 14, 2026. An additional 45% vests on the tenth day after Minerva publicly announces that its Phase 3 confirmatory trial of roluperidone in schizophrenia has achieved the primary endpoint at the 12-week timepoint on a statistically significant basis. The remaining 30% vests on the tenth day after Minerva publicly announces safety data from the 40-week relapse assessment phase, provided Kaul is providing services under a consulting agreement dated November 14, 2025 on each vesting date.
Minerva Neurosciences (NERV) reported a routine equity compensation grant to a non-employee director. On 11/14/2025, the director received a stock option to purchase 9,500 shares of Minerva common stock at an exercise price of $4.11 per share. The option vests in equal quarterly installments over three years, with the first installment vesting on February 14, 2026, as long as the individual continues to serve as a non-employee director on each vesting date. The option expires on November 13, 2035, giving a long-term incentive aligned with the company’s share performance.